Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Ixazomib and Dexamethasone in High Risk Smoldering Multiple Myeloma
NCT02697383Phase 1Completed
- Sponsor
- Memorial Sloan Kettering Cancer Center
- Start
- Feb 2016
- Primary completion
- May 2024
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, open-label, single-arm trial of ixazomib in smoldering multiple myeloma (SMM), sponsored by Memorial Sloan Kettering Cancer Center. Primary endpoint: Best Overall Response. Started Feb 2016; status: completed.
02
Drugs
ixazomib
03
Conditions
smoldering multiple myeloma (SMM)
Beyond the preview
Go deeper on NCT02697383.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02697383.